Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Study Information
Alliance Study ID: A091302
NCT Study ID (ClinicalTrials.gov): NCT02143726
Alliance Committee: Experimental Therapeutics
Disease or Cancer Type: Thyroid & Neuroendocrine / Endocrine Cancers
Alliance Study Chair: Eric Sherman, MD
Status: ACTIVE_NOT_RECRUITING
Study Description
This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib tosylate versus sorafenib tosylate alone in treating patients with advanced radioactive iodine refractory thyroid cancer. Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of everolimus to sorafenib tosylate may cause more shrinkage of thyroid cancer and may prevent it from growing but it could also cause more side effects than sorafenib tosylate alone. It is not yet known whether this treatment with sorafenib tosylate and everolimus is better, the same, or worse than sorafenib tosylate alone.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Locations (21)
Mayo Clinic in Florida
Jacksonville, Florida 32224-9980
United States
Northwestern University
Chicago, Illinois 60611
United States
Siouxland Regional Cancer Center
Sioux City, Iowa 51101
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan 48109
United States
Mayo Clinic
Rochester, Minnesota 55905
United States
Nebraska Methodist Hospital
Omaha, Nebraska 68114
United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey 07920
United States
Memorial Sloan Kettering Monmouth
Middletown, New Jersey 07748
United States
Memorial Sloan Kettering Bergen
Montvale, New Jersey 07645
United States
Memorial Sloan Kettering Commack
Commack, New York 11725
United States
Memorial Sloan Kettering Westchester
Harrison, New York 10604
United States
Memorial Sloan Kettering Cancer Center
New York, New York 10065
United States
Memorial Sloan Kettering Sleepy Hollow
Sleepy Hollow, New York 10591
United States
Memorial Sloan Kettering Nassau
Uniondale, New York 11553
United States
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina 28328
United States
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina 27534
United States
Wayne Memorial Hospital
Goldsboro, North Carolina 27534
United States
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina 28546
United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania 19111
United States
Mercy Health System
Janesville, Wisconsin 53547
United States
Data Sources & Contacts
Full trial details
For more Information